Findacure has found an innovative way to use this financial tool to fund drug repurposing research for rare diseases. This is the rare disease drug repurposing social impact bond - RDDR SIB for short.. But how would it work?. Our SIB is based on the premise that successfully repurposing low cost generic drugs for rare disease patients will save the NHS money. Rare diseases left untreated cost the NHS lots in surgery, care, appointments, hospital, stays, and much more - a cost that can be significantly reduced by a cheap, repurposed treatment. The NHS can then use a portion of these savings to reimburse Findacure for the cost of the clinical trial. We will use this reimbursement to pay back private investors, whose money was required to initially run the trial. Surplus reimbursement will be invested by us in more clinical trials: the project is self-sustaining and non-profit.. ...
Along the lines that have been discussed in a recent Frontiers short paper, here is a list of our patent discussions in the December 2017 drug repurposing special issue of ASSAY and Drug Development Technologies:. WO/2017/059389 (Kythera Biopharmaceuticals, USA): Statins as an alternative to liposuction and cryolipolysis. WO/2017/060308 (AB Science, France): Masitinib switches to human use. WO/2017/066421 (Ovid Therapeutics, USA): Eplivanserin for improving cognition in psychoses. WO/2017/068143 (Individual, Germany): BAY 11-7082 or dimethyl fumarate for adiposity or cardiovascular diseases. WO/2017/080919 (Freiburg University, Germany): Roflumilast for metabolic lipid disorders. WO/2017/081609 (Individuals): Febuxostat: from gout to neurology. WO/2017/085407 (Pierre et Marie Curie University et al., France): Mirabegron, an overactive bladder drug, for macular degeneration. WO/2017/091644 (AZ Therapies, USA): Cromolyn for cerebral ischemia and dementia. WO/2017/096013 (Cornell University, USA): ...
Drug repurposing or re-profiling has been the hallmark to bring strong business growth and the trend is being followed by majority of the pharmaceutical an
1. Probably the most famous repurposing case is that of thalidomide. First used as a sedative in the 1950s thalidomide is infamous for causing birth defects in babies of women who were prescribed it to treat nausea whilst pregnant. It was, however, successfully and safely repurposed in 1998 to treat leprosy and in 2006 to treat the blood cancer multiple myeloma.. 2. Discovered in 1972 on Easter Island, rapamycin, also known as Sirolimus, is produced by a soil bacterium Streptomyces hygroscopicus. Its ability to suppress the immune system led to its original approved use to prevent rejection in organ transplantation in 1999. It has since been successfully repurposed to treat two rare diseases, autoimmune lymphoproliferative syndrome (ALPS) and lymphangioleiomyomatosis, a lung disease.. 3. Lomitapide was originally used to lower cholesterol and triglycerides. It went on to be approved in 2012 by the Food and Drug Administration (FDA) and in 2013 by the European Commission to treat patients with ...
Prosarix Ltd provides computational drug discovery to partner companies and generates preclinical development compounds for out-licensing utilising its proprietary ProtoDiscovery platform.
Schrodinger is hiring a Senior Computational Drug Discovery Scientist, with an estimated salary of $80000 - $100000. This Life Sciences job in Science & Education is in Portland, OR 97201.
... , Computational Chemistry List, Resource for Computational Chemists, molecular modeling, and associated archives
Drawer Repurposed To Bathroom Wall Cabinet {Tutorial, jenson curved single vanity 116cm marble top. Drawer Repurposed To Bathroom Wall Cabinet {Tutorial. irinadorofeeva.com. /
8. Surg Neurol 1979; 12367. 56в58,60 These failure rates are likely higher because the tumor propranolol clorhidrato tableta can fall within the area beyond the radiation dose fall-off. Propranolol drug indication T, Habib E, Mekkaoui M, Brassier D, Elhadad Indiccation (2002) Laparoscopic tension-free repair propranolol drug indication anterior abdominal wall incisional and ventral hernias with an intraperitoneal Gore- Tex mesh prospective study and review of the literature.
Insilico Medicine will present its recent advances in applying deep learning techniques to drug discovery and repurposing at the Strategic Partnerships in Drug Repurposing conference in Boston taking place at the Wyndham Boston Beacon Hill Oct. 27-28.
Victoza is a core molecule of Novo Nordisk and almost contribute about 25% of the companys total diabetes care revenues. Victoza sales shot up 21% to DKK 11.5 billion ($1.7 billion) in the first half of 2017 compared to the same period the year prior.. Clinical Trial for New Indication Approval:. Victozas new indication is based on data from the late-stage LEADER trial that enrolled more than 9,300 type 2 diabetes who were at high risk of major adverse CV events. Patients receiving Novos drug had an average 13% reduction in their risk of a three-component endpoint that included heart attack, stroke and CV death compared to placebo.. Future Growth or Focus area for the brand:. ...
The search for additional indications for modafinil naturally focused on diseases associated with wake deficits and somnolence. The effects of the drug in an animal model of sleep-disordered breathing suggested that modafinil might be effective in reducing sleepiness associated with sleep apnea,50 and this was subsequently demonstrated in the clinic.51-53 Other disorders where somnolence or sedation was concomitant with the disease, e.g., Parkinsons disease,54-56 myotonic dystrophy,57-60 fibromyalgia,61 amyotrophic lateral sclerosis,62 multiple sclerosis,63 cerebral lymphoma,64 or resulting from the side-effects of other medications such as antidepressants,65 antipsychotics,66 dopaminergic D2 agonists,67,68 opioids,69 or valproic acid,70 have also proven to be amenable to treatment with modafinil.. Likewise modafinil has been applied with equal success to treating the fatigue coexisting with other serious diseases, including multiple sclerosis,71,72 pain,73 and acquired immunodeficiency ...
Forward-Looking Statements Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the advancement, therapeutic indication and use, safety, efficacy, tolerability, mechanism of action and potential of lorcaserin; the significance of the PWG s re-adjudication and the CSF study, including the potential use of the results; the response to the CRL for the lorcaserin NDA, including related plans, activities and timing; the therapeutic indication of APD811; and Arena s views, focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena s expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are ...
Cerebral palsy (CP) is the most common developmental disability amongst children in the United States, and encompasses a heterogenous group of motor impairment syndromes caused by a non-progressive lesion of the brain. The cause is typically unknown, and the lesion can arise either pre-natally, peri-natally or post-natally. Patients can have mild functional impairments or severely limited mobility and motor control. Many patients have spasticity and hypertonia. CP is a long-term chronic medical condition that requires long-term supportive care services as well as physiotherapy and occupational therapy. In the US, approximately 764,000 children and adults are living with CP, and it is estimated another 8,000-10,000 babies develop CP each year.. ...
The Ilizarov fixator is indicated for trauma induced conditions involving the upper and lower limbs and in all conditions in which mechanical trans-skeletal traction is necessary, such as in comminuted and multi-fragmented fractures, even with loss of bone substance. By avoiding long hospital stays and joint complications resulting from immobilisation, this technique allows a patient to resume his or her usual activities within a few days, with minimum impediment due in the main to the size of the fixator.. ...
Bourne and his colleagues screened 274 drugs approved for human use against 1730 TB proteins with known structures (about 40 percent of the proteome). They reported their results in the November 4 issue of PLoS Computational Biology.. Starting with 274 approved drugs that had been co-crystallized with at least one human or animal protein-a total of 962 drug-receptor complexes-Bourne and his team narrowed the search space further using an algorithm called SOIPPA (Sequence Order Independent Profile-Profile Alignment Algorithm), which was developed by Bourne and Lei Xie, PhD, research scientist at UCSD. For each drug-receptor complex, SOIPPA searched for TB proteins with structurally similar binding sites. Then Bournes team virtually docked the drug into these TB proteins to look for matches.. "Theres a computer cost associated with our method, but you can do a whole pathogen proteome on a 100-node cluster in a couple of weeks," Bourne says.. They connected 123 drugs to 447 TB proteins, and ...
http://ift.tt/eA8V8J. The northern hemispheres summer is ending and that is definitely bad news. The good news is that this was not a silly season in health and healthcare research.. Heres the best and worst news of the summer.. The best. Drug repurposing screening reveals possible candidates for anti-Zika therapy. Developing a new drug is a long process, but the Zika virus outbreak has created a global health emergency and a pressing need for therapies that is incompatible with the timings of drug development. This led to a major study published in Nature Medicine in which over 6,000 compounds were screened for possible drug repurposing, including approved drugs, clinical trial drug candidates and pharmacologically active compounds. This screening allowed the identification of compounds that were able to inhibit Zika infection, suppress the effects of infection in neurons, or inhibit viral replication. Furthermore, combination treatments using neuroprotective and antiviral compounds showed a ...
Biovista Vizit is a visual exploration tool for biomedical literature based on NCBI PubMed. Vizit allows scientists to search and explore a biomedical domain, such as a disease, a pathway or a gene, and to create biomedical networks and graphs.
You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our cookies policy. ...
This team repurposed e-waste to help minimize the high number of power outages in hospitals in Africa. This effort supports a number of goals outlined by the UN relative to health care, as well as the effort of developing a global partnership to promote development in this area. Kimberly Bawden
Peripheral arterial disease (PAD) results from atherosclerosis that leads to blocked arteries and reduced blood flow, most commonly in the arteries of the legs. PAD clinical trials to induce angiogenesis to improve blood flow conducted in the last decade have not succeeded. We have recently constructed PADPIN, protein-protein interaction network (PIN) of PAD, and here we combine it with the drug-target relations to identify potential drug targets for PAD. Specifically, the proteins in the PADPIN were classified as belonging to the angiome, immunome, and arteriome, characterizing the processes of angiogenesis, immune response/inflammation, and arteriogenesis, respectively. Using the network-based approach we predict the candidate drugs for repositioning that have potential applications to PAD. By compiling the drug information in two drug databases DrugBank and PharmGKB, we predict FDA-approved drugs whose targets are the proteins annotated as anti-angiogenic and pro-inflammatory, respectively. Examples
SOM Biotech (SOM), a leading drug repurposing company based in Barcelona, Spain , has determined and validated an entirely new usage for Nippon Chemiphars marketed hypertension
Health,... ... ...New Indication is One of Three FDA Approvals Spanning Lilly Neuroscien... ...,FDA,Approves,Symbyax(R),as,First,Medication,for,Treatment-Resistant,Depression,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
FDA Grants Priority Review for Potential New Indication for Lillys Verzenio(TM) (abemaciclib) as Initial Treatment of Advanced Breast Cancer
The current standard of care for the treatment of venous thromboembolism (VTE), including DVT and pulmonary embolism, is low molecular weight heparin injections followed by a vitamin K antagonist, such as warfarin, these are also used as standard therapy for stroke prevention in atrial fibrillation. Heparins require administration by injection, which can cause inconvenience and discomfort. Vitamin K antagonists can be difficult to manage with regularly changing doses and many interactions with food and other drugs among their limitations.. Rivaroxaban has the potential to replace the dual-drug approach in deep vein thrombosis treatment with a single-drug approach that can potentially simplify the patient pathway and improve efficiencies in delivering treatment to patients in need.. Approval by the European Committe in these new indications is expected to follow in the fourth quarter of 2011.. "Patients have waited over 50 years for new treatments which offer an alternative to traditional ...
As EuroPCR 2012 gets under way today, Medtronic, Inc. (NYSE: MDT) announced that the Resolute Integrity Coronary Stent System has received European regulatory approval for several new indications, making it the ......MDT
[New indications for transcranial Doppler--huge steps forward].: Huge steps forward in understanding and treatment of ischemic stroke happened in the last sever
Cambridge, UK, September 3rd 2010 - Prosarix announces successful completed of EEDA funded program on the development of chiral SAR panels for drug discovery.. Pharmaceutical companies develop biologically active lead compounds using a variety of methods e.g. "rational" approaches (fragment-based discovery, computer-based design) or screening large collections of molecules (HTS - high throughput screening). From an identified "hit", large numbers of structurally-related compounds are synthesised in order to optimise both the drug-like properties of the molecule and to define the maximum scope of protectable IP.. A recent trend by companies working in this structure activity relationship (SAR) stage of drug discovery is to utilise more complex molecular structures, which typically possess chirality, i.e. the compound can exist in two or more stereospecific forms. As a consequence single isomers are now preferred as building blocks for use during construction of SAR compound series, even at the ...
I think this is a very promising development for the applications of computation to drug discovery, but as a scientist in the field myself I am even more excited about the volume of useful data this effort must have generated. This is simply because, based on their model, it seems that every molecule that Nimbus prioritizes or discards necessarily goes through their computational pipeline: this would be rather unique. The corpus of data this process generates is presumably locked inside Nimbuss virtual vaults, but I think they and Schrodinger should release at least a high level abstraction of it to let everyone figure out what worked and what did not. At the very least it would transform Nimbuss success from an impressive black box to a comprehensible landscape of computational workflows. ...
Join expert speakers from EMD Serono, Roche, BMS and more. Engage with those sharing similar problems to you, and hear how industry leaders are overcoming their biggest challenges.
The availability of safe and effective radiation countermeasures for the military and civilian population represents a significant unmet medical need. To expedite the development of countermeasures for life-threating situations, the United States Food and Drug Administration (US FDA) has implemented the "Animal Rule" which applies to the development and evaluation of drugs and biologics to reduce or prevent life-threatening conditions caused by exposure to lethal or permanently disabling agents where human efficacy trials are neither feasible nor ethical. In addition, the FDA has introduced several incentives (fast track, orphan drug status, and emergency use authorization [EUA]) to attract drug sponsors to develop such agents for human use. Repurposing is vital to make drugs available for life-threatening conditions. Drugs are commonly repurposed for new indications not originally envisioned. By repurposing a drug, it can be made available for human use much quicker, but this pathway also ...
Penn Nursings Heath Schmidt, a neuropharmacologist and director of the Laboratory of Neuropsychopharmacology, is part of a team of Penn res...
If it is not feasible to develop licensed drugs to the stage that they can actually be prescribed for a new indication, can we justify, either ethically or economically, the undertaking of proof-of-concept studies using off-patent medications? Without a financial incentive it is very difficult to repurpose off patent drugs for a new indication. Therefore, we need a political solution to allow the repurposing of off-patent drugs by other stakeholders or Big Pharma. ...
© The New Use For Asprin 100% Satisfaction Guaranteed! Easy And Fast Shipping Processing, [[THE NEW USE FOR ASPRIN]] Medication with Secured Cheapest prices.
Back when Martin Shkreli was CEO of Retrophin, he managed to grab a few headlines by buying an old rare-disease drug, Thiola, and raising the price 2000%. Now that hes on to his next company, Turing Pharmaceuticals, hes done himself one better, by buying another old drug and boosting the price 5000%.
Dust off those old drugs. A Stanford University group has developed a computational method for finding potential new uses for previously approved drugs. And two papers published Wednesday in the
R version 3.5.1 Patched (2018-07-12 r74967) ## Platform: x86_64-pc-linux-gnu (64-bit) ## Running under: Ubuntu 16.04.5 LTS ## ## Matrix products: default ## BLAS: /home/biocbuild/bbs-3.8-bioc/R/lib/libRblas.so ## LAPACK: /home/biocbuild/bbs-3.8-bioc/R/lib/libRlapack.so ## ## locale: ## [1] LC_CTYPE=en_US.UTF-8 LC_NUMERIC=C ## [3] LC_TIME=en_US.UTF-8 LC_COLLATE=C ## [5] LC_MONETARY=en_US.UTF-8 LC_MESSAGES=en_US.UTF-8 ## [7] LC_PAPER=en_US.UTF-8 LC_NAME=C ## [9] LC_ADDRESS=C LC_TELEPHONE=C ## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C ## ## attached base packages: ## [1] stats graphics grDevices utils datasets methods base ## ## other attached packages: ## [1] ccdata_1.7.0 limma_3.38.0 lydata_1.7.0 ccmap_1.8.0 ## [5] crossmeta_1.8.0 ## ## loaded via a namespace (and not attached): ## [1] Biobase_2.42.0 httr_1.3.1 tidyr_0.8.2 ## [4] bit64_0.9-7 jsonlite_1.5 viridisLite_0.3.0 ## [7] foreach_1.4.4 shiny_1.1.0 assertthat_0.2.0 ## [10] stats4_3.5.1 doRNG_1.7.1 blob_1.1.1 ## [13] yaml_2.2.0 ...
MetaDrug is the very first systems pharmacology platform in the market, designed primarily for small molecule discovery programmes at drug companies and academic centres. Building this benchmark platform, we relied on customer feedback and our own vision for the field. Now, we are very glad that NIH agrees with our development goals", stated Julie Bryant, Vice President, business development. "Our customers particularly like the flexibility of the system which makes their version of MetaDrug specific to their chemistry space and informatics environment. We will continue working in this direction. New funding will also allow us to expand applicability of MetaDrug in other areas of biological effects of drug action such as pharmacogenomics, prediction of side effects and new therapeutic indications.". "This funding will enable us to expand the scope of MetaDrug integrating predictive algorithms for ADME/TOX properties, and add a database of ligand-protein interactions from other species, in ...
The discovery and development of a new drug, whether it is a new chemical entity or new molecular entity or a cell based therapy for particular therapeutic indications or diseases is generally divided into phases.
The Course provides students with the essential concepts of general Pharmacology including Pharmacodynamics and Pharmacokinetics with particular emphasis on the action of drugs, receptors, the agonist-antagonist concept, therapeutic indications, absorption, distribution, metabolism and excretion. The student is expected to understand the interactions between drugs both at a pharmacodynamic and at a pharmacokinetic level and the undesired effects of drugs. Additionally, the student is expected to be familiar with the drugs that act on the central, automonous and somatic nervous system, adrenergic and cholinergic pharmacology, injectable, local and inhalation anaesthetics, anticoagulants, inotropes, vasodilators, calcium channel blockers, anti-arrhythmia agents, ACE-inhibitors, diuretics, thyroid hormones and anti-thyroid drugs, natural and natural and synthetic glucocorticoids, Nonsteroidal Antiinflammatory Drugs (NSAIDs), drugs active on the gastrointestinal functions and on the respiratory ...
NEWARK, Calif., April 25, 2016-- Revance Therapeutics, Inc., a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the Company will release first quarter 2016 financial results on Monday, May 9, 2016 after the close of market. Revance will host a corresponding conference call and a...
RESULTS: During this study period, a total of 54 patients underwent TEVAR for thoracic or thoracoabdominal aneurysm with the use of EndoAnchors at our institution. Twenty-seven cases were performed as the index operation. Twenty-seven cases were considered redo operations. EndoAnchors were deployed for therapeutic and prophylactic indications. Mean follow-up was 9.6±8.8 months. EndoAnchors were used for therapeutic indications in 31.5% of patients and for prophylactic indications in 68.5%. The technical success of EndoAnchor deployment was 99.8%. The overall initial technical success of the operation was 98.1%. There were no instances of graft migration. The overall endoleak rate was 5.4% with prophylactic EndoAnchor use and 11.8% with therapeutic use. Aortic-related reintervention was required in 13.5% of patients who received prophylactic EndoAnchor placement and 23.5% of patients who received therapeutic EndoAnchor placement. Only one reintervention was performed for EndoAnchor failure. A p ...
Provides concise definitions for some 230 terms frequently used by clinicians, researchers, teachers, and others working in the field of substance abuse. Explanatory definitions, often including psychoactive effects, symptomatology, sequelae, and therapeutic indications, are given for each general class of psychoactive drugs, including alcohol and tobacco, and for some related classes. In producing the lexicon, WHO aims to encourage consistency in the use of terms and in the understanding of their meaning. The lexicon also provides a convenient reference to concepts and terminology recommended by WHO. The lexicon defines the main diagnostic categories for alcohol, tobacco, and other drug use, as well as key concepts in scientific or popular use, the social and health aspects of drug use, and problems related to use. In its coverage of treatment modalities and prevention strategies, the lexicon has aimed to define what is not self-explanatory. General indications are given of the historical ...
Since its approval in 2011, the multiple sclerosis drug fingolimod (Gilenya) has already undergone three early benefit assessments, all of which were mainly based on the approval study TRANSFORMS. After a new modification of the therapeutic indication by the regulatory authorities, the Federal Joint Committee again commissioned the German Institute for Quality and Efficiency in Health Care to examine the added benefit of the drug in accordance with the Act on the Reform of the Market for Medicinal Products.. ...
Smart biotech traders can avoid the dangers tied with chasing the news by employing some, or all, of the following tactics.. The first is really simple: think longer term. I understand that the promise of investing in cures for Ebola or MERS might seem like a winner for a few weeks or even months, but what happens when the prevalence of these somewhat rare diseases begins to die down? Your best course of action is to approach each trade with the mindset of holding for at least a couple of years. This way your investing thesis has time to play out, you can potentially take advantage of the effects of time and compounding, and when you sell youll pay much less in capital gains taxes.. Secondly, think long and hard about the therapeutic indications that the biotech stock youre buying is targeting. Infectious disease companies targeting MERS and Ebola may be hit or miss, but chronic global conditions such as HIV/AIDS, influenza, hepatitis B, hepatitis C, cancer, and so on, offer an opportunity to ...
Section 4.1 (Therapeutic indications): - Updated to read Erythromycin is indicated for the prophylaxis and treatment of infections caused by erythromycin sensitive organisms. Section 4.2 (Posology and method of administration): - Updated dilution and administration guidelines to enable user to have a clearer understanding of recommended use of product. Section 4.3 (Contraindications): - Updated hypersensitivity statement. - Removal of statement Use in patients with serious impairment of liver function as this is documented in section 4.4. - Added statement Bolus injection (IV push) is an unacceptable route of administration. Section 4.4 (Special warnings and precautions for use): - Added warning regarding rare reports of prolongation of QTc interval and ventricular arrhythmias in patients receiving IV erythromycin. - Added warning alerting user to benzyl alcohol in product associated with fatal Gasping Syndrome in premature patients. - Expansion of statement regarding reports of patients ...
The SmPC has been updated following an EU harmonisation work-sharing procedure.. Sections 4.1 and 4.2 have been updated, with consequential changes to sections 4.4. Information on prophylactic use in VTE for non-surgical patients is also included.. Changes are detailed below:. 4.1 Therapeutic indications - revised wording Prophylaxis of venous thromboembolism in adult patients undergoing surgery, particularly orthopaedic, general or oncological surgery.. Prophylaxis of venous thromboembolism in non-surgical adult patients immobilised due to acute medical illness including: acute heart failure, acute respiratory failure, severe infections, active cancer, as well as exacerbation of rheumatic diseases.. Prevention of clotting in extracorporeal circuits during haemodialysis and haemofiltration in adults.. 4.2 Posology and method of administration - revised wording Posology. Prophylaxis of thromboembolic events in adults:. Administration is by subcutaneous injection.. Surgical patients at moderate ...
CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.  CCR5 appears to play…
01 April 2016. Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to improve rehabilitation for stroke patients with the use of non-invasive brain stimulation, today announces the appointment of John Liedtky as VP of Commercialization, General Manager US, effective from 1 April 2016. Mr. Liedtky will also join Nexstim Management Team and will be responsible of Pre-Surgical Mapping business and commercial development of therapeutic indications. At the same time, Nexstim announces the planned retirement of John Hardin, Vice President, Pre-surgical Mapping from Nexstims Management Team on 6 May 2016.. John Liedtky is a global healthcare executive with extensive experience in the medical device and equipment space, having previously held Global Marketing Vice Presidency Roles at DJO Global, COVIDIEN and BREG Inc. John Liedtky is an expert in leading cross-functional teams through the complete product life-cycle, from upstream development to strategic downstream marketing and ...
Elicats.com - All rights reserved © 2012 - 2020 - The reproduction, even partial, of all contents present on the site is forbidden without explicit authorization. The contents are for information purposes only and in no case may they constitute a prescription for a treatment or replace the specialist examination or direct relationship with your doctor/veterinary - The products and statements on specific products are not intended to diagnose, treat, cure or prevent any disease. The treatment methods presented are alternative therapy remedies and are therefore not scientifically recognized. In these pages are inserted "Homeopathic preparations of efficacy not scientifically validated and without approved therapeutic indications" The information on treatments should not be seen as a promise to cure. All information on special diets and dietary supplements for pets is for information purposes only. This information serves as a general guideline, cannot be applied to all pets or considered as an ...